Skip to content
Research Monograph

FOXO4-D-Retro-Inverso Peptide

Also Known AsFOXO4-DRI · D-Retro-Inverso FOXO4 peptide · ES2

Molecular Weight~4800 g/mol
Discovered2017
Citations3 peer-reviewed
Research Areas4 domains
Background

Designed by Peter de Keizer and colleagues at Erasmus University Medical Center (Rotterdam). The peptide is a D-retro-inverso version of the FOXO4 segment that interacts with p53, making it protease-resistant while retaining binding specificity. Published in Cell in 2017 as a targeted senolytic approach.

Mechanisms of Action

How FOXO4-DRI Works

01

p53-FOXO4 Interaction Disruption

FOXO4-DRI competes with endogenous FOXO4 for binding to p53 in senescent cells. In senescence, FOXO4 sequesters p53 in PML (promyelocytic leukemia) nuclear bodies, preventing p53 from translocating to the cytoplasm where it would trigger mitochondrial apoptosis. FOXO4-DRI displaces this interaction, freeing p53 to execute its pro-apoptotic program.

FOXO4p53PML nuclear bodies
02

Selective Senescent Cell Apoptosis

The selectivity of FOXO4-DRI for senescent cells arises because the FOXO4-p53 survival mechanism is uniquely active in senescent cells. Non-senescent cells do not depend on FOXO4-mediated p53 sequestration for survival, so FOXO4-DRI does not trigger apoptosis in proliferating or quiescent normal cells.

senescent cell apoptosiscaspase-3mitochondrial p53 translocation
03

SASP Reduction

By eliminating senescent cells, FOXO4-DRI indirectly reduces the senescence-associated secretory phenotype (SASP) — the pro-inflammatory cocktail of cytokines (IL-6, IL-8, IL-1beta), MMPs, and growth factors secreted by senescent cells that drives chronic sterile inflammation and tissue dysfunction in aging.

SASPIL-6IL-8IL-1betaMMP secretion
Evidence-Graded Research Areas

Published Research

Strong
Moderate
Emerging
Preclinical

Cellular Senescence Clearance

Strong

The foundational 2017 Cell paper demonstrated that FOXO4-DRI selectively induces apoptosis in senescent cells (identified by p21, SA-beta-gal, and SASP markers) while sparing non-senescent cells in vitro. Mechanism confirmed through FOXO4-p53 co-immunoprecipitation and PML body disruption assays.

Aging & Healthspan in Mice

Moderate

In naturally aged and fast-aging (XpdTTD/TTD) mice, FOXO4-DRI treatment restored fitness (running wheel activity), fur density, and renal function. Treated mice showed reduced senescent cell burden (p16INK4a, p21 markers) and reduced SASP-driven tissue inflammation compared to vehicle controls.

Chemotherapy-Induced Senescence

Preclinical

Doxorubicin-induced senescence in mice was counteracted by FOXO4-DRI treatment, reducing hepatotoxicity and restoring liver function markers. This suggests potential utility for clearing therapy-induced senescent cells that persist after cancer treatment and drive long-term side effects.

Organ-Specific Aging Research

Preclinical

Preclinical evidence demonstrates effects on kidney function restoration in aged mice (improved creatinine clearance, reduced tubular damage) and improved skin thickness/fur density. Organ-specific effects correlate with local senescent cell burden reduction.

Safety Profile

Preclinical studies in mice showed the peptide was well-tolerated with no observed toxicity to non-senescent tissues. Mild and transient side effects (reduced food intake, weight loss) were observed in initial treatment phases but resolved. No human clinical trials have been conducted. The D-retro-inverso design confers protease resistance, extending in vivo half-life. Theoretical risk of immunogenicity as a large peptide has not been specifically assessed.

Handling & Storage

FOXO4-DRI is a large, complex peptide (~48 residues, all D-amino acids). Reconstitute carefully with bacteriostatic water. Store lyophilized powder at -20°C. Reconstituted solution at 2-8°C, use within 14 days. The D-amino acid composition provides protease resistance but the molecule is sensitive to aggregation — do not vortex.

References & Citations

Peer-Reviewed Literature

  1. 1

    Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging

    Baar MP, Brandt RMC, Putavet DA, et al.

  2. 2

    The fountain of youth by targeting senescent cells?

    de Keizer PLJ.

    Trends in Molecular Medicine, 2017PubMed 28188067DOI
  3. 3

    Cellular senescence: a translational perspective

    Kirkland JL, Tchkonia T.

    EBioMedicine, 2017PubMed 28416161DOI
Frequently Asked Questions

FOXO4-DRI FAQ

What is FOXO4-DRI?

FOXO4-DRI is a D-retro-inverso peptide designed to selectively eliminate senescent cells (senolytics). It works by disrupting the interaction between FOXO4 and p53 that senescent cells use to avoid apoptosis. By displacing FOXO4 from p53, it allows p53 to trigger mitochondrial apoptosis specifically in senescent cells.

What does 'D-retro-inverso' mean?

D-retro-inverso (DRI) is a peptide engineering strategy where the amino acid sequence is reversed and all L-amino acids are replaced with D-amino acids. This maintains a similar side-chain topology to the original L-peptide while rendering the molecule resistant to protease degradation, extending its biological half-life.

Why does FOXO4-DRI only kill senescent cells?

The selectivity comes from the specific vulnerability it targets. Only senescent cells rely on FOXO4 sequestering p53 in PML nuclear bodies to avoid apoptosis. Normal proliferating or quiescent cells do not depend on this mechanism, so disrupting the FOXO4-p53 interaction has no effect on their viability.

Has FOXO4-DRI been tested in humans?

No human clinical trials have been conducted as of the current literature. All published data comes from in vitro senescent cell models and in vivo mouse studies (naturally aged, fast-aging, and chemotherapy-treated). Clinical translation remains an active area of research.

How should FOXO4-DRI be stored?

Store lyophilized FOXO4-DRI at -20°C. Reconstitute gently with bacteriostatic water — do not vortex, as the large DRI peptide is prone to aggregation. Refrigerate reconstituted solution at 2-8°C and use within 14 days.

Available for Research

FOXO4-DRI Products

All compounds 99%+ purity, verified by Janoshik Analytical. GMP-manufactured lyophilized powder.

Buy 3, Save 30%
FOX
Lyophilized Powder
99%

The zombie cell killer — selectively destroys the senescent cells that cause aging, inflammation, and tissue decline, while leaving healthy cells untouched.

  • Selectively kills senescent 'zombie' cells that cause aging
  • Restored fitness, hair density, and kidney function in aged mice
$296.99
Related Compounds

Explore Related Research

Buy 3, Save 30%trending
Epi
Lyophilized Powder
99%

Turns back your biological clock — activates the enzyme that rebuilds telomeres, resets melatonin production, and extended lifespan in every model tested.

  • Activates telomerase — literally lengthens your DNA's aging clock
  • Resets melatonin production for better sleep as you age
$109.99
Buy 3, Save 30%bestseller
GHK
Lyophilized Powder
99.72%

GHK-Cu

100mg

The anti-aging powerhouse — tightens skin, grows thicker hair, fades scars, and resets 4,000+ genes back toward a youthful state.

  • Visibly reduces wrinkles and tightens loose skin
  • Stimulates thick, healthy hair growth and reduces thinning
$89.99
Buy 3, Save 30%
Thy
Lyophilized Powder
99%

Immune system supercharger — activates your T-cells and dendritic cells for maximum pathogen defense. Used clinically worldwide for hepatitis B and immune support.

  • Supercharges immune system function and resilience
  • Used clinically for hepatitis B, cancer immunotherapy support
$131.99

Disclaimer: This monograph is provided for educational and research purposes only. G26x Peptides products are sold exclusively as research chemicals. They are not intended for human consumption, therapeutic use, or as dietary supplements. All research should be conducted in compliance with applicable laws and institutional review board protocols. Information presented here is sourced from published peer-reviewed literature and does not constitute medical advice.